← Back to patent-cliff list
CAS 50-00-0
FormaldehydeFormalin
Codes: (VIII)270899-2-a, (XXXI)638294-1-d, (XIV)101438-55-a, Rifampicin-014, (XIII)909096-1-a, (X)909096-2-a,(X)909096-2-b
Application context (from source-drug indications)
Major depressive disorderEsketamine HydrochlorideSuicidal ideationEsketamine HydrochlorideDepressive disorderEsketamine HydrochlorideAnaesthesiaEsketamine HydrochlorideTreatment-resistant depressionEsketamine HydrochloridePainEsketamine HydrochlorideSystolic heart failureFinerenoneDiastolic heart failureFinerenoneHeart failureFinerenoneChronic renal impairmentFinerenoneDiabetic nephropathyFinerenoneType 2 diabetesFinerenoneBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateMycobacterium tuberculosis infectionEthambutol Hydrochloride/Rifampicin/IsoniazidPancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelMycobacterium tuberculosis infectionRifampicinMycobacterium leprae infectionRifampicinPulmonary tuberculosisRifampicinMeningococcal meningitisRifampicinCOVID-19RifampicinRespiratory viral infectionRifampicinNon-small cell lung cancerIruplinalkib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Esketamine Hydrochloride | Tier B — Position early | 2029 |
| Finerenone | Tier C — Watch / trade | 2030 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Ethambutol Hydrochloride/Rifampicin/Isoniazid | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Rifampicin | Tier C — Watch / trade | - |
| Iruplinalkib | Tier C — Watch / trade | - |
| Eptazocine hydrobromide | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-Chloro-2-iodobenzene→4-Cyclohexanone→2-(2-Chlorophenyl)cyclohexanone→(E)-Di-tert-butyl azodiformate→Di-tert-butyl 1-[(1S)-1-(2-chlorophenyl)-2-oxocyclohexyl]hydrazine-1,2-dicarboxylate→(-)-2(S)-Amino-2-(2-chlorophenyl)cyclohexanone→(1S)-2'-Chloro-1-isocyanato-6-methoxy-1,2,3,4-tetrahydro-1,1'-biphenyl→Formaldehyde→(2S)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(2R,3S,4R)-3,4-Diacetoxy-3,4-dihydro-2H-pyran-2-yl]methyl acetate→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hex-2-enopyranoside→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hexopyranoside→Methyl 2,3-dideoxy-alpha-D-erythro-hexopyranoside→(6S)-6-(Benzyloxy)cyclohex-2-en-1-one→(2S,3S,6S)-2-(Iodomethyl)-6-methoxytetrahydro-2H-pyran-3-ol→(2S,3S,6S)-3-(Benzyloxy)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran→(3S,6S)-3-(Benzyloxy)-6-methoxy-2-methylenetetrahydro-2H-pyran→(2S,5R)-2-(Benzyloxy)-5-hydroxycyclohexanone→lithium carbanide→(6S)-6-(Benzyloxy)-1-methylcyclohex-2-en-1-ol→(4S)-4-(Benzyloxy)-3-methylcyclohex-2-en-1-one→Chloro(ethynyl)magnesium→Formaldehyde→(2R,3S,4S)-4-(Benzyloxy)-2-(hydroxymethyl)-3-methyl-3-vinylcyclohexanone→(2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanone→(1S,2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanol→2-[[(1R,2S,3S,6S)-3-(Benzyloxy)-6-(methoxymethoxy)-2-methyl-2-vinylcyclohexyl]methoxy]tetrahydro-2H-pyran
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→Acetic acid (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ester→Formaldehyde→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-8-[(pyrrolidin-1-yl)methyl]-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-8-[(piperidin-1-yl)methyl]-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(morpholin-4-yl)methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→1-[[(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-(Acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-8-yl]methyl]piperidine-4-carboxylic acid→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-[(2,6-Dimethylpiperidin-1-yl)methyl]-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(4-methylpiperazin-1-yl)methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-[(Diethylamino)methyl]-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate→(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-[(Dimethylamino)methyl]-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
(2R,3S,4R)-3,4-Diacetoxy-3,4-dihydro-2H-pyran-2-yl]methyl acetate→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hex-2-enopyranoside→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hexopyranoside→Methyl 2,3-dideoxy-alpha-D-erythro-hexopyranoside→(6S)-6-(Benzyloxy)cyclohex-2-en-1-one→(2S,3S,6S)-2-(Iodomethyl)-6-methoxytetrahydro-2H-pyran-3-ol→(2S,3S,6S)-3-(Benzyloxy)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran→(3S,6S)-3-(Benzyloxy)-6-methoxy-2-methylenetetrahydro-2H-pyran→(2S,5R)-2-(Benzyloxy)-5-hydroxycyclohexanone→lithium carbanide→(6S)-6-(Benzyloxy)-1-methylcyclohex-2-en-1-ol→(4S)-4-(Benzyloxy)-3-methylcyclohex-2-en-1-one→Chloro(ethynyl)magnesium→Formaldehyde→(2R,3S,4S)-4-(Benzyloxy)-2-(hydroxymethyl)-3-methyl-3-vinylcyclohexanone→(2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanone→(1S,2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanol→2-[[(1R,2S,3S,6S)-3-(Benzyloxy)-6-(methoxymethoxy)-2-methyl-2-vinylcyclohexyl]methoxy]tetrahydro-2H-pyran
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.